Bing C. Wang
Director of Finance/CFO bei CELLECTIS S.A.
Vermögen: - $ am 31.03.2024
Profil
Bing C.
Wang was the founder and had founded Refuge Biotechnologies, Inc. in 2016, where he held the title of Chief Executive Officer & Director until 2021.
He is currently the Chief Financial Officer at Cellectis SA since 2022.
Dr. Wang's former positions include Director-Healthcare Investment Banking at Barclays Capital, Inc. and Director at KBP Biosciences USA, Inc. from 2017 to 2018.
Dr. Wang's education history includes an undergraduate degree from The Trustees of Columbia University in The City of New York, a graduate and doctorate degree from Princeton University, and an MBA from Columbia Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CELLECTIS SA
-.--% | 14.02.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Bing C. Wang
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLECTIS S.A. | Director of Finance/CFO | 10.02.2022 |
Ehemalige bekannte Positionen von Bing C. Wang
| Unternehmen | Position | Ende |
|---|---|---|
Refuge Biotechnologies, Inc.
 Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Founder | 01.12.2021 |
KBP Biosciences USA, Inc.
 KBP Biosciences USA, Inc. Miscellaneous Commercial ServicesCommercial Services KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ. | Director/Board Member | 01.10.2018 |
Barclays Capital, Inc.
 Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Head of Private Banking | - |
Ausbildung von Bing C. Wang
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| Princeton University | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CELLECTIS S.A. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Finance |
KBP Biosciences USA, Inc.
KBP Biosciences USA, Inc. Miscellaneous Commercial ServicesCommercial Services KBP Biosciences engages in conducting biotechnological research to develop therapies for patients. The company was founded by Huang Zhenhua in and is headquartered in Princeton, NJ. | Commercial Services |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Commercial Services |
